# Efficacy and Safety Study of AVB-S6-500 in Patients With Platinum-Resistant Recurrent Ovarian Cancer

> **NCT03639246** · PHASE1 · COMPLETED · sponsor: **Aravive, Inc.** · enrollment: 53 (actual)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** AVB-S6-500
- **DRUG:** Paclitaxel (Pac)
- **DRUG:** Pegylated liposomal doxorubicin (PLD)
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03639246
- **Lead sponsor:** Aravive, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-06
- **Primary completion:** 2021-01-08
- **Final completion:** 2022-12-30
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2023-02-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03639246

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03639246, "Efficacy and Safety Study of AVB-S6-500 in Patients With Platinum-Resistant Recurrent Ovarian Cancer". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT03639246. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*